Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04515836 · ClinicalTrials.gov registry record · Phase 2
Olaparib in Patients With HRD Malignant Mesothelioma
A Phase 2 study of Mesothelioma and Homologous Recombination Deficiency, sponsored by University of Chicago.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
- 1
- Study location
NCT04515836 is a Phase 2 study of Mesothelioma and Homologous Recombination Deficiency that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 56 participants, below the 197-participant average among 46 other Mesothelioma trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04515836, a Phase 2 study of Mesothelioma and Homologous Recombination Deficiency, is actively recruiting participants, sponsored by University of Chicago.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
- 1
- Study location
Study Summary
In this study, researchers will give olaparib (a drug) to mesothelioma patients who have specific changes in their DNA (known as gene mutations). Researchers will give this drug to each patient on the study to find out if it will help the patient's tumor shrink or stop growing.
Conditions Studied
Interventions
- DRUG Olaparib
Study Locations (1)
Illinois
- University of Chicago Medical Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2021-02-19 |
| Est. Completion | 2028-04-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04515836
The ClinicalTrials.gov registry entry for NCT04515836 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 197-participant average among 46 other Mesothelioma trials with a reported enrollment target (72% lower). The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Mesothelioma appearing as the primary indexed condition, and to 1 intervention - of which Olaparib is the first listed.
NCT04515836 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT04515836 about?
NCT04515836 is a clinical study titled "Olaparib in Patients With HRD Malignant Mesothelioma". In this study, researchers will give olaparib (a drug) to mesothelioma patients who have specific changes in their DNA (known as gene mutations). Researchers will give this drug to each patient on the study to find out if it will help the patient's tumor shrink or stop growing.
What is the current status of trial NCT04515836?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2021-02-19. Estimated completion is 2028-04-15.
What conditions does trial NCT04515836 study?
This clinical trial studies the following conditions: Mesothelioma, Homologous Recombination Deficiency.
What interventions are being tested in trial NCT04515836?
The interventions under investigation include: Olaparib (DRUG).
Who is sponsoring clinical trial NCT04515836?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04515836 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mesothelioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Sacituzumab Govitecan in People With Mesothelioma
RECRUITING · Phase 2
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
RECRUITING · Phase 2
-
MAGIC AKI: Magnesium for the Prevention of HIOC-Associated AKI
RECRUITING · Phase 2
-
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
RECRUITING · Phase 2
-
A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma
RECRUITING · Phase 2
-
Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.